Carmell is a biotechnology company focused on developing and commercializing plasma-based bioactive materials (PBMs) that contain a concentration of natural regenerative factors to treat bone fractures and accelerate healing in various clinical settings. The patented technology is based on biologically active materials manufactured from allogenic human blood plasma, and the company is focused on the sports medicine market to produce better clinical outcomes and reduce healthcare costs.